REGULATORY

• Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
  March 27, 2026

• MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
  March 27, 2026

• AMED Warns Projects without Japan Return May Miss Startup Funding
  March 26, 2026

• Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
  March 25, 2026

• Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
  March 25, 2026

• Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
  March 24, 2026

• Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
  March 24, 2026

• Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
  March 24, 2026

• MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
  March 23, 2026

• Japan Hands Out Orphan Tags to Ianalumab, Bleximenib, and Lots More Drugs
  March 23, 2026

• Ex-LDP Lawmaker, Pharmacist Jun Matsumoto Dies at 75
  March 23, 2026

• LDP Project Team Flags Drug Pricing as Key to Investment
  March 19, 2026

• Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
  March 18, 2026

• MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
  March 18, 2026

• MHLW Orders Label Revisions for Antiepileptics and Other Drugs
  March 18, 2026

• MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
  March 17, 2026

• Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
  March 17, 2026

• Gaku Hashimoto to Return as Skipper of LDP Team on Drug Innovation
  March 17, 2026

• Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
  March 16, 2026

• Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
  March 16, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »